PEGCETACOPLAN

Also sold under the name of EMPAVELI.

In the Patient recruiting phase.  Estimate Starting clinical trials for the treatment of Cold Agglutinin Disease  March 2022.  Estimated to run through June 2024.

Trial Studies at:
The Oncology Institute of Hope and Innovation
Whittier, California, United States

Lakes Research
Miami Lakes, Florida, United States

This medication is used to treat paroxysmal nocturnal hemoglobinuria. (PNH).  A type of Anemia in which too many of the body’s Red Blood Cells are broken down.  Reducing remaining healthy Blood Cells required to transport oxygen throughout the body. This medication works by blocking the part of the immune system that damages Red Blood Cells.

Link to ClinicalTrials.gov/PEGCETACOPLAN

 928 total views,  2 views today